Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
Weidinger S, Blauvelt A, Papp KA, Reich A, Lee CH, Worm M, Lynde C, Kataoka Y, Foley P, Wei X, Wong W, Solente AC, Weber C, Adelman S, Davey S, Hurbin F, Rynkiewicz N, Yen K, O'Malley JT, Bernigaud C.
Weidinger S, et al. Among authors: weber c.
J Allergy Clin Immunol. 2024 Nov 8:S0091-6749(24)01175-8. doi: 10.1016/j.jaci.2024.10.031. Online ahead of print.
J Allergy Clin Immunol. 2024.
PMID: 39522654